Also, ligand-independent EPHA2 signaling triggered the adoption of a therapy-induced, BRAF inhibitor resistant-metastatic melanoma phenotype through PI3K-AKT signaling [128,129,130]. The gene discussed is EPHA2; the disease is melanoma.